Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis

S.G. Royce, Yuben Moodley, C.S. Samuel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Inflammatory cell infiltration, cytokine release, epithelial damage, airway/lung remodelling and fibrosis are central features of inflammatory lung disorders, which include asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Although the lung has some ability to repair itself from acute injury, in the presence of ongoing pathological stimuli and/or insults that lead to chronic disease, it no longer retains the capacity to heal, resulting in fibrosis, the final common pathway that causes an irreversible loss of lung function. Despite inflammation, genetic predisposition/factors, epithelial-mesenchymal transition and mechanotransduction being able to independently contribute to airway remodelling and fibrosis, current therapies for inflammatory lung diseases are limited by their ability to only target the inflammatory component of the disease without having any marked effects on remodelling (epithelial damage and fibrosis) that can cause lung dysfunction independently of inflammation. Furthermore, as subsets of patients suffering from these diseases are resistant to currently available therapies (such as corticosteroids), novel therapeutic approaches are required to combat all aspects of disease pathology. This review discusses emerging therapeutic approaches, such as trefoil factors, relaxin, histone deacetylase inhibitors and stem cells, amongst others that have been able to target airway inflammation and airway remodelling while improving related lung dysfunction. A better understanding of the mode of action of these therapies and their possible combined effects may lead to the identification of their clinical potential in the setting of lung disease, either as adjunct or alternative therapies to currently available treatments. (C) 2013 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)250-260
Number of pages11
JournalPharmacology & Therapeutics
Volume141
Issue number3
Early online date25 Oct 2013
DOIs
Publication statusPublished - Mar 2014

Cite this

@article{2ce6aab3b1b744e9935eb9932304212a,
title = "Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis",
abstract = "Inflammatory cell infiltration, cytokine release, epithelial damage, airway/lung remodelling and fibrosis are central features of inflammatory lung disorders, which include asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Although the lung has some ability to repair itself from acute injury, in the presence of ongoing pathological stimuli and/or insults that lead to chronic disease, it no longer retains the capacity to heal, resulting in fibrosis, the final common pathway that causes an irreversible loss of lung function. Despite inflammation, genetic predisposition/factors, epithelial-mesenchymal transition and mechanotransduction being able to independently contribute to airway remodelling and fibrosis, current therapies for inflammatory lung diseases are limited by their ability to only target the inflammatory component of the disease without having any marked effects on remodelling (epithelial damage and fibrosis) that can cause lung dysfunction independently of inflammation. Furthermore, as subsets of patients suffering from these diseases are resistant to currently available therapies (such as corticosteroids), novel therapeutic approaches are required to combat all aspects of disease pathology. This review discusses emerging therapeutic approaches, such as trefoil factors, relaxin, histone deacetylase inhibitors and stem cells, amongst others that have been able to target airway inflammation and airway remodelling while improving related lung dysfunction. A better understanding of the mode of action of these therapies and their possible combined effects may lead to the identification of their clinical potential in the setting of lung disease, either as adjunct or alternative therapies to currently available treatments. (C) 2013 Elsevier Inc. All rights reserved.",
keywords = "Inflammatory lung diseases, Epithelial damage, Fibrosis, TFF2, Relaxin, HDAC inhibitors, Stem cells, IDIOPATHIC PULMONARY-FIBROSIS, HISTONE DEACETYLASE INHIBITORS, MESENCHYMAL STEM-CELLS, MUC5B PROMOTER POLYMORPHISM, GROWTH-FACTOR-BETA, IN-VITRO, EXTRACELLULAR-MATRIX, EPITHELIAL-CELLS, STROMAL CELLS, MOUSE MODEL",
author = "S.G. Royce and Yuben Moodley and C.S. Samuel",
year = "2014",
month = "3",
doi = "10.1016/j.pharmthera.2013.10.008",
language = "English",
volume = "141",
pages = "250--260",
journal = "Pharmacology & Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",
number = "3",

}

Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. / Royce, S.G.; Moodley, Yuben; Samuel, C.S.

In: Pharmacology & Therapeutics, Vol. 141, No. 3, 03.2014, p. 250-260.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis

AU - Royce, S.G.

AU - Moodley, Yuben

AU - Samuel, C.S.

PY - 2014/3

Y1 - 2014/3

N2 - Inflammatory cell infiltration, cytokine release, epithelial damage, airway/lung remodelling and fibrosis are central features of inflammatory lung disorders, which include asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Although the lung has some ability to repair itself from acute injury, in the presence of ongoing pathological stimuli and/or insults that lead to chronic disease, it no longer retains the capacity to heal, resulting in fibrosis, the final common pathway that causes an irreversible loss of lung function. Despite inflammation, genetic predisposition/factors, epithelial-mesenchymal transition and mechanotransduction being able to independently contribute to airway remodelling and fibrosis, current therapies for inflammatory lung diseases are limited by their ability to only target the inflammatory component of the disease without having any marked effects on remodelling (epithelial damage and fibrosis) that can cause lung dysfunction independently of inflammation. Furthermore, as subsets of patients suffering from these diseases are resistant to currently available therapies (such as corticosteroids), novel therapeutic approaches are required to combat all aspects of disease pathology. This review discusses emerging therapeutic approaches, such as trefoil factors, relaxin, histone deacetylase inhibitors and stem cells, amongst others that have been able to target airway inflammation and airway remodelling while improving related lung dysfunction. A better understanding of the mode of action of these therapies and their possible combined effects may lead to the identification of their clinical potential in the setting of lung disease, either as adjunct or alternative therapies to currently available treatments. (C) 2013 Elsevier Inc. All rights reserved.

AB - Inflammatory cell infiltration, cytokine release, epithelial damage, airway/lung remodelling and fibrosis are central features of inflammatory lung disorders, which include asthma, chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Although the lung has some ability to repair itself from acute injury, in the presence of ongoing pathological stimuli and/or insults that lead to chronic disease, it no longer retains the capacity to heal, resulting in fibrosis, the final common pathway that causes an irreversible loss of lung function. Despite inflammation, genetic predisposition/factors, epithelial-mesenchymal transition and mechanotransduction being able to independently contribute to airway remodelling and fibrosis, current therapies for inflammatory lung diseases are limited by their ability to only target the inflammatory component of the disease without having any marked effects on remodelling (epithelial damage and fibrosis) that can cause lung dysfunction independently of inflammation. Furthermore, as subsets of patients suffering from these diseases are resistant to currently available therapies (such as corticosteroids), novel therapeutic approaches are required to combat all aspects of disease pathology. This review discusses emerging therapeutic approaches, such as trefoil factors, relaxin, histone deacetylase inhibitors and stem cells, amongst others that have been able to target airway inflammation and airway remodelling while improving related lung dysfunction. A better understanding of the mode of action of these therapies and their possible combined effects may lead to the identification of their clinical potential in the setting of lung disease, either as adjunct or alternative therapies to currently available treatments. (C) 2013 Elsevier Inc. All rights reserved.

KW - Inflammatory lung diseases

KW - Epithelial damage

KW - Fibrosis

KW - TFF2

KW - Relaxin

KW - HDAC inhibitors

KW - Stem cells

KW - IDIOPATHIC PULMONARY-FIBROSIS

KW - HISTONE DEACETYLASE INHIBITORS

KW - MESENCHYMAL STEM-CELLS

KW - MUC5B PROMOTER POLYMORPHISM

KW - GROWTH-FACTOR-BETA

KW - IN-VITRO

KW - EXTRACELLULAR-MATRIX

KW - EPITHELIAL-CELLS

KW - STROMAL CELLS

KW - MOUSE MODEL

U2 - 10.1016/j.pharmthera.2013.10.008

DO - 10.1016/j.pharmthera.2013.10.008

M3 - Article

VL - 141

SP - 250

EP - 260

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

SN - 0163-7258

IS - 3

ER -